Kitchener, Canada
Nicoya, a Canadian biotechnology company, embodies its mission of improving human life by helping scientists succeed. Founded in 2012 by Ryan Denomme, Nicoya has harnessed nanotechnology to make scientific instruments more affordable and user-friendly.
With a team surpassing 100 employees, Nicoya specializes in pioneering biosensor technology for analyzing biomolecular interactions. Their flagship product, Alto, is the world's first digital high-throughput benchtop SPR instrument, revolutionizing drug discovery by reducing the sample volume needed and accelerating the process. This innovation enables biotechnology and pharmaceutical companies to expedite their market presence with greater efficiency.
In its last funding round, Nicoya secured a $20.00M Series A investment on 16 December 2021, backed by investors including MaRS IAF, Export Development Canada, Garage Capital, Whitecap Venture Partners, Business Development Bank of Canada, and Agilent Technologies. Positioned at the intersection of biotechnology and sensor tech, Nicoya stands as a promising opportunity in the sector.
